Products for Research Use Only

Cenisertib (benzoate)

CAT: 0804-HY-13072BSize: 1 EachDry Ice: NoHazardous: No
Product image 1
1 / 1
CAT#:0804-HY-13072BSize:1 Each
Selected
24/48H Stock Items & 2 to 6 Weeks non Stock Items.
Quick Request Actions
Description
Cenisertib (AS-703569) benzoate is an ATP-competitive multi-kinase inhibitor that blocks the activity of Aurora-kinase-A/B, ABL1, AKT, STAT5 and FLT3. Cenisertib benzoate induces major growth-inhibitory effects by blocking the activity of several different molecular targets in neoplastic mast cells (MC) . Cenisertib benzoate inhibits tumor growth in xenograft models of pancreatic, breast, colon, ovarian, and lung tumors and leukemia[1][2][3].
CAS Number
1145859-64-8
Product Name Alternative
AS-703569 (benzoate) ; R-763 (benzoate)
UNSPSC
12352005
Target
Akt; Aurora Kinase; Bcr-Abl; FLT3; STAT
Type
Reference compound
Related Pathways
Cell Cycle/DNA Damage; Epigenetics; JAK/STAT Signaling; PI3K/Akt/mTOR; Protein Tyrosine Kinase/RTK; Stem Cell/Wnt
Field of Research
Cancer
Assay Protocol
https://www.medchemexpress.com/cenisertib-benzoate.html
Smiles
OC(C1=CC=CC=C1)=O.NC([C@H]2[C@@](C=C3)([H])C[C@@]3([H])[C@H]2NC4=NC(NC5=CC(C)=C(N6CCN(CC6)C)C=C5)=NC=C4F)=O
Molecular Formula
C31H36FN7O3
Molecular Weight
573.66
References & Citations
[1]Peter B, et al. Drug-induced inhibition of phosphorylation of STAT5 overrides drug resistance in neoplastic mast cells. Leukemia. 2018 Apr;32 (4) :1016-1022.|[2]McLaughlin J, et al. Preclinical characterization of Aurora kinase inhibitor R763/AS703569 identified through an image-based phenotypic screen. J Cancer Res Clin Oncol. 2010 Jan;136 (1) :99-113.|[3]Maryam Shariati, et al. Targeting AKT for cancer therapy. Expert Opin Investig Drugs. 2019 Nov;28 (11) :977-988.
Shipping Conditions
Room temperature
Scientific Category
Reference compound1
Clinical Information
Phase 1